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Abstract
Aim
Heart failure (HF) increases the risk of thromboembolic events (TE). Study in a Caucasian
population has shown that the CHA2DS2-VASc score predicts TE among HF patients with-
out atrial fibrillation. We sought to assess the usefulness of the CHA2DS2-VASc score in
predicting TE in an Asian population and refine the scoring system to improve its predictabil-
ity of TE among HF patients in sinus rhythm.
Methods
A total of 1,202 consecutive patients who were admitted to our institution for new-onset HF
from 2005 to 2012 and without atrial fibrillation or anticoagulation were retrospectively
reviewed.
Results
The mean age was 77.6 ± 12.2 years and 51.7% were female. After 36.2 ± 30.1 months,
113 (9.4%) developed TE. The annual incidence was 0.54%, 1.54%, 2.98% and 5.04% per
year in those who had a CHA2DS2-VASc score of 1, 2–3, 4–5 and6, respectively. In multi-
variate analysis, age75 years [Hazard ratio (HR) 2.59, 95% confidence interval (CI) 1.23–
5.46, p = 0.012), chronic ischemic heart disease (HR 1.54, 95% CI 1.02–2.31, p = 0.040)
and chronic kidney disease (HR 1.66, 95% CI 1.09–2.53, p = 0.018) independently predicted
TE. Incorporation of chronic ischemic heart disease and chronic kidney disease into the
CHA2DS2-VASc score significantly increased the area under the Receiver Operating Curve
from 0.57 (95% CI 0.54–0.59) to 0.61 (95% CI 0.55–0.66; p = 0.022).
Conclusion
The CHA2DS2-VASc score is useful for stratification of the risk of TE among HF patients in
sinus rhythm. Incorporation of chronic ischemic heart disease and chronic kidney disease
into the score modestly improves its predictive value.
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Introduction
Heart failure (HF) is an emerging epidemic that affects 26 million people worldwide.[1]
Although the condition is well-known for its poor prognosis due to pump failure and/or sud-
den death, significant morbidity and mortality also results from an increased risk of thrombo-
embolism.[2–5] In fact, HF is the second most common cause of cardioembolic stroke after
atrial fibrillation (AF).[6] Left ventricular dysfunction is associated with intra-cardiac stasis,
endocardial and endothelial dysfunction, and a hypercoagulable state, all of which promote
thrombus formation and subsequent embolization.[2, 7–9] In stark contrast to AF, in which
long-term anticoagulation is shown to substantially reduce the risk of thromboembolic events
(TE), randomized controlled trials in HF patients in sinus rhythm have failed to demonstrate a
net clinical benefit of oral anticoagulation over antiplatelet agents or placebo.[10–13] In the
largest Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction Trial (WARCEF) that
involved 2,305 HF patients in sinus rhythm, warfarin conferred a reduction in ischemic stroke
by 48% compared with aspirin that was offset by an increase in major hemorrhage.[13] None-
theless this may also suggest that there exists a high-risk subset of HF patients in sinus rhythm
who may derive a net clinical benefit from oral anticoagulation therapy.
The CHA2DS2-VASc score is a risk stratification tool to predict TE among patients with
non-valvular AF.[14–18] This simple clinical prediction rule has been well validated in different
populations and is recommended by current guidelines for the stratification of patients with AF
for antithrombotic therapy.[15–20] Recently, the CHA2DS2-VASc score has also been shown in
a Danish registry to predict TE among HF patients in sinus rhythm.[4, 21] Nevertheless this has
not been evaluated in other populations. Furthermore, since the CHA2DS2-VASc score is based
on studies in AF populations[14], clinical parameters not included in the CHA2DS2-VASc score
may have incremental value for the prediction of TE among HF patients in sinus rhythm. We
therefore performed this study to 1) determine independent clinical predictors of TE among
HF patients in sinus rhythm; 2) assess the usefulness of the CHA2DS2-VASc score in predicting
TE in Asian HF patients; 3) assess the value of incorporating independent clinical predictors
into the CHA2DS2-VASc score to predict TE in HF patients in sinus rhythm.
Materials and Methods
Study design
This was a retrospective observational study based on the Hong Kong Heart Failure Registry.
The study protocol was approved by the local Institutional Review Board. Details of the regis-
try have been described in a previous study.[22] In summary, patients at Queen Mary Hospital,
Hong Kong who were diagnosed with new-onset HF based on the Framingham Heart Study
criteria from January 2005 to April 2012, were identified via the computerized clinical manage-
ment system.[23] Demographic data, cardiovascular risk factors, clinical presentation, echo-
cardiographic findings and laboratory test results on admission were recorded and clinical
outcomes were followed. Patients who were younger than 18 years of age, had incomplete fol-
low-up data, or were prescribed anticoagulation were excluded. Prior myocardial infarction
was defined as a myocardial infarction that occurred during or prior to the index hospitaliza-
tion. Chronic ischemic heart disease was defined as either a significant coronary artery stenosis
diagnosed by angiography or myocardial ischemia diagnosed by stress testing in those without
prior myocardial infarction. Chronic kidney disease was defined as an estimated glomular fil-
tration rate (eGFR) <60 ml/min/1.73m2 by the Modification of Diet in Renal Disease formula.
[24] HF with preserved ejection fraction (HFPEF) was defined as HF with left ventricular ejec-
tion fraction (LVEF)40%.[25] The CHA2DS2-VASc score of each patient at diagnosis of HF
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was calculated (C: congestive heart failure [1 point]; H: hypertension [1 point]; A2: age 65–74
years [1 point] and age75 years [2 points]; D: diabetes mellitus [1 point]; S: prior stroke or
transient ischemic attack [2 points]; V: vascular disease, defined as prior myocardial infarction
or peripheral vascular disease [1 point]; and Sc: sex category = female [1 point]).[14]. The pri-
mary outcome was TE and included ischemic stroke, transient ischemic attack and peripheral
thromboembolism. All diagnoses were adjudicated by two cardiologists in accordance with
the updated consensus statements and guidelines.[24, 26–30]
Statistical analysis
Continuous variables are expressed as mean ± standard deviation, and categorical variables are
presented in frequency tables. Statistical comparison of continuous variables was performed
using Student’s t test, and catagorical variables with Fisher’s exact test or Chi-square test. Kaplan-
Meier survival analysis with the log-rank test was used to compare TE-free survival of different
patient groups. Hazard ratio (HR) and 95% confidence interval (CI) of clinical variables to pre-
dict primary outcome among HF patients in sinus rhythm were determined by a multivariate
Cox regression model using a p value<0.1 for inclusion. The prognostic performance of predic-
tion models of TE was assessed using c-statistics and compared using the DeLong test. Internal
validation of the final prediction model was evaluated by bootstrapping 1,000 random samples.
The optimism was estimated by comparing the final model performance on each bootstrapped
sample to that of the original data. The corrected area under the Receiver-Operating Characteris-
tics (ROC) curve was computed by subtracting the optimism from the original area under the
ROC curve. A 2-tailed p value<0.05 was considered statistically significant. Calculations were
performed using SPSS software (version 21.0) and R package (version 3.3.1).
Results and Discussion
Patient selection, exclusion and clinical outcomes are summarized in Fig 1. From January
2005 to April 2012, 1,940 patients were admitted to our hospital for new-onset HF. After
excluding 164 patients (8.5%) who were prescribed warfarin, the final analysis included 1,776
patients. The mean age of the cohort was 78.7 ± 11.7 years and 965 (54.3%) were female. Of the
858 patients (48.3%) who had a technically adequate echocardiogram during the admission,
the mean LVEF was 47.0 ± 16.0% and 59.3% of patients had a LVEF40%, i.e., HFPEF.
Clinical characteristics and outcomes of patients with and without AF
A total of 574 patients (32.3%) had prior or concomitant AF, and the remaining 1,202 were in
sinus rhythm (67.7%). Table A in S1 File summarizes their clinical characteristics. After a
mean follow-up of 36.2 ± 30.1 months, 190 patients with new-onset HF developed TE, of
whom 169 had an ischemic stroke and 21 a transient ischemic attack. The annual incidence of
TE in our cohort was 3.55% per year (95% CI: 3.41–3.69). Of the 190 TE, 77 developed in
those with AF and 113 in patients in sinus rhythm. The annual incidence of TE among HF
patients with AF and in sinus rhythm was 5.23% per year (95% CI 4.88–5.62) and 2.91% per
year (95% CI 2.79–3.05), respectively. Fig A in S1 File depicts the Kaplan-Meier survival analy-
sis comparing TE-free survival of HF patients with AF and those in sinus rhythm.
Predictors of TE among HF patients in sinus rhythm
Among HF patients in sinus rhythm, those who developed TE were more likely to have
hypertension (82.3% vs. 72.5%, p = 0.025), chronic ischemic heart disease (40.7% vs. 24.0%,
p<0.001) and chronic kidney disease (69.0% vs. 55.7%, p = 0.024. Table 1). They also had a
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higher CHA2DS2-VASc score (4.89 ± 1.40 vs. 4.52 ± 1.54, p = 0.014) and were more likely to be
prescribed aspirin (54.9% vs. 43.5%, p = 0.022. Table 1). In univariate analyses, increasing age
(age 65–74 years: HR 2.41, 95% CI1.07–5.41, p = 0.033; age75 years: HR 3.10, 95% CI 1.50–
6.43, p = 0.002), hypertension (HR 1.88, 95% CI 1.16–3.06, p = 0.010), diabetes mellitus (HR
1.46, 95% CI 1.01–2.11, p = 0.045), chronic ischemic heart disease (HR 1.95, 95% CI 1.34–
2.83) and chronic kidney disease (HR 2.15, 95% CI 1.44–3.21, p<0.001) were associated with
an increased risk of TE (Table 2). In multivariate analysis, increasing age (age75 years: HR
2.59, 95% CI 1.23–5.46, p = 0.012), chronic ischemic heart disease (HR 1.54, 95% CI 1.02–2.31,
p = 0.040) and chronic kidney disease (HR 1.66, 95% CI 1.09–2.53, p = 0.018) remained inde-
pendently associated with TE (Table 2). Importantly, the use of aspirin, clopidogrel, and anti-
HF medications such as betablockers, renal-angiotensin-aldosterone inhibitors and mineralo-
corticoid receptor antagonists was not associated with a reduced risk of TE in HF patients in
sinus rhythm (Table 2).
The CHA2DS2-VASc score and TE among HF patients in sinus rhythm
Kaplan-Meier survival analysis showed that the TE-free survival of HF patients in sinus
rhythm reduced with increasing CHA2DS2-VASc score (log-rank p<0.001. Fig 2A). As shown
in Fig 2B, the annual incidence of TE increased with an increasing CHA2DS2-VASc score. Spe-
cifically, for patients who had a CHA2DS2-VASc score of 1, i.e. no other risk factor other than
HF alone, the annual incidence of TE was 0.54% per year (95% CI 0.45–0.67). For those who
had a CHA2DS2-VASc score of 2–3, the annual incidence of TE was 1.54% per year (95% CI
Fig 1. A flow chart showing selection, exclusion and clinical outcomes of our study population. SR–
sinus rhythm.
doi:10.1371/journal.pone.0169095.g001
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1.41–1.70). Nevertheless for patients who had a CHA2DS2-VASc score of 4–5 and6, the
annual incidence of TE was as high as 2.98% (95% CI 2.81–3.18) and 5.04% (95% CI 4.59–
5.60) per year, respectively. The area under the ROC curve for the CHA2DS2-VASc score to
predict TE was 0.57 (95% CI 0.54–0.59. Fig 3).
Modification of the CHA2DS2-VASc score to improve prediction of TE
among HF patients in sinus rhythm
Based on the additional independent predictors of TE identified in the multivariate cox regres-
sion analysis, we developed the CHA2DS2-VASc-HK2 by incorporating 1) chronic ischemic
heart disease, and 2) chronic kidney disease into CHA2DS2-VASc score as follows: C: conges-
tive heart failure [1 point]; H: hypertension [1 point]; A2: age 65–74 years [1 point] and age
Table 1. Baseline characteristics of 1,202 heart failure patients in sinus rhythm with and without thromboembolic events.
All With TE No TE p-value
(n = 1,202) (n = 113) (n = 1,089)
Age, (years) 77.6±12.2 78.7±9.2 77.5±12.5 0.195
Female, n (%) 622 (51.7) 61 (54.0) 561 (51.5) 0.623
Smoker, n (%) 399 (33.2) 34 (30.1) 365 (33.5) 0.529
Drinker, n (%) 163 (13.6) 17 (15.0) 146 (13.4) 0.664
Hypertension, n (%) 883 (73.5) 93 (82.3) 790 (72.5) 0.025*
Diabetes mellitus, n (%) 473 (39.4) 53 (46.9) 420 (38.6) 0.086
Chronic ischemic heart disease, n (%) 308 (25.6) 46 (40.7) 262 (24.0) <0.001*
Prior myocardial infarction, n (%) 78 (6.5) 9 (8.0) 69 (6.3) 0.545
Peripheral vascular disease, n (%) 45 (3.7) 8 (7.1) 37 (3.4) 0.064
Prior ischemic stroke / TIA, n (%) 160 (13.3) 16 (14.2) 144 (13.2) 0.771
Availability of echocardiography 583 (48.5) 61 (54.0) 522 (47.9) 0.236
LVEF#, (%) 45.9±16.4 47.9±14.1 45.7±16.6 0.252
HFPEF#, n (%) 254 (56.4) 36 (59.0) 293 (56.1) 0.685
eGFR, ml/min/1.73m2, (%) 57.1±30.4 51.8±24.7 57.6±30.9 0.022*
Chronic kidney disease, n (%) 685 (57.0) 78 (69.0) 607 (55.7) 0.024*
CHA2DS2-VASc score 4.56±1.53 4.89±1.40 4.52±1.54 0.014*
1 43 (3.6) 1 (2.3) 42 (97.7)
2–3 229 (19.1) 15 (6.6) 214 (93.4)
4–5 629 (52.3) 58 (9.2) 571 (90.8)
6 301 (25.0) 39 (13.0) 262 (87.0)
Medications, n (%)
Aspirin 536 (44.6) 62 (54.9) 474 (43.5) 0.022*
Clopidogrel 61 (5.1) 7 (6.2) 54 (5.0) 0.503
Betablockers 480 (39.9) 53 (46.9) 427 (39.2) 0.130
ACEI/ARB 619 (68.9) 61 (54.0) 558 (51.2) 0.621
MRA 44 (3.7) 3 (2.7) 41 (3.8) 0.792
Frusemide 965 (80.3) 91 (68.4) 874 (80.3) 1.000
Insulin 107 (8.9) 10 (8.8) 97 (8.9) 1.000
Statin 336 (28.0) 26 (23.0) 310 (28.5) 0.270
*p<0.05.
#Calculation was based on 349 patients with AF and 603 patients without AF who had LVEF measured on admission.
TIA–Transient ischemic attack; ACEI–angiotensin-converting enzyme inhibitors; ARB–angiotensin receptor blockers; MRA–mineralocorticoid receptor
antagonists.
doi:10.1371/journal.pone.0169095.t001
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75 years [2 points]; D: diabetes mellitus [1 point]; S: prior stroke or transient ischemic attack
[2 points]; V: peripheral vascular disease and aortic disease [1 point]; and Sc: sex category =
female [1 point]; H: ischemic heart disease, including myocardial infarction or chronic ische-
mic heart disease [1 point]; K: chronic kidney disease [2 points]. In general, the TE-free sur-
vival of HF patients in sinus rhythm also reduced with an increasing CHA2DS2-VASc-HK2
score (log-rank p<0.001. Fig 4A). In particular, patients with a CHA2DS2-VASc-HK2 score of
1–3 had good TE-free survival, patients with a CHA2DS2-VASc-HK2 score of 4–7 had interme-
diate TE-free survival, and those with a CHA2DS2-VASc-HK2 score8 had the worst TE-free
survival. The annual incidence of TE was 0.86% (95% CI 0.78–0.96), 2.76% (95% CI 2.61–2.92)
and 5.50% (95% CI 4.99–6.12) per year for patients who had a CHA2DS2-VASc-HK2 score of
1–3, 4–7 and8, respectively (Fig 4B). The area under the ROC curve for the CHA2DS2-
VASc-HK2 score to predict TE was superior to that of the CHA2DS2-VASc score [0.61 (95%
CI 0.55–0.66) vs. 0.57 (95% CI 0.54–0.59), p = 0.022. Fig 3]. When assessed by Cox regression
analysis, a CHA2DS2-VASc-HK2 score of 4–7 was associated with a 3-fold increase in risk of
TE and a CHA2DS2-VASc-HK2 score8 was associated with a 6-fold increase in the risk of
TE among HF patients in sinus rhythm (Table 3).
Table 2. Univariate and multivariate predictors of thromboembolic events in 1,202 heart failure patients in sinus rhythm.
Univariate analysis Multivariate analysis
HR (95% CI) p-value HR (95% CI) p-value
Age 0.008* 0.039*
<65 Reference Reference
65–74 2.41 (1.07–5.41) 0.033* 2.09 (0.92–4.71) 0.077
75 3.10 (1.50–6.43) 0.002* 2.59 (1.23–5.46) 0.012*
Female 1.05 (0.73–1.52) 0.795
Smoker 0.86 (0.58–1.29) 0.476
Drinker 1.05 (0.63–1.76) 0.845
Hypertension 1.88 (1.16–3.06) 0.010* 1.43 (0.87–2.36) 0.157
Diabetes mellitus 1.46 (1.01–2.11) 0.045* 1.20 (0.81–1.78) 0.359
Chronic ischemic heart disease 1.95 (1.34–2.83) 0.001* 1.54 (1.02–2.31) 0.040*
Prior myocardial infarction 1.33 (0.67–2.63) 0.409
Peripheral vascular disease 2.05 (1.00–4.21) 0.050 1.69 (0.81–3.53) 0.165
Prior ischemic stroke / TIA 1.41 (0.83–2.39) 0.205
HFPEF# 0.94 (5.64–1.57) 0.810
Chronic kidney disease 2.15 (1.44–3.21) <0.001* 1.66 (1.09–2.53) 0.018*
Medications
Aspirin 1.39 (0.96–2.02) 0.081 1.18 (0.80–1.76) 0.401
Clopidogrel 1.12 (0.52–2.41) 0.772
Betablockers 1.17 (0.81–1.69) 0.404
ACEI/ARB 0.85 (0.59–1.23) 0.390
MRA 0.61 (0.19–1.92) 0.398
Frusemide 0.89 (0.56–0.14) 0.634
Insulin 1.18 (0.62–2.26) 0.616
Statin 0.80 (0.52–1.24) 0.316
*p<0.05.
#Calculation was based on 349 patients with AF and 603 patients without AF who had LVEF measured on admission.
TIA–transient ischemic attack; ACEI–angiotensin-converting enzyme inhibitors; ARB–angiotensin receptor blockers; MRA–mineralocorticoid receptor
antagonists.
doi:10.1371/journal.pone.0169095.t002
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Internal validation of the CHA2DS2-VASc-HK2 score
Internal validation of the final prediction model was performed as described. Cox regression
analyses of 1000 bootstrapped samples resulted in the same independent predictors of TE
(Table B in S1 File). The optimism-corrected area under the ROC curve was 0.61 (95% CI
0.55–0.66). We further compared the ability of the CHA2DS2-VASc-HK2 in predicting TE
among patients with HFREF and HFPEF using z-test. The area under the ROC curve for the
CHA2DS2-VASc-HK2 to predict TE in patients with HFREF and HFREF were not significantly
different [0.63 (95% CI 0.52–0.73) and 0.70 (95% CI 0.60–0.80), respectively, (p = 0.368)].
Fig 2. Risk of thromboembolic events among heart failure patients in sinus rhythm according to their
CHA2DS2-VASc score. (A) Kaplan-Meier curves for thromboembolic event-free survival. Log-rank: 19.714.
P<0.001. (B) Annual incidence of thromboembolic events. CHA2DS2-VASc = 1: 0.54% per year (95% CI 0.45–
0.67); CHA2DS2-VASc = 2–3: 1.54% per year (95% CI 1.41–1.70); CHA2DS2-VASc = 4–5: 2.98% per year (95% CI
2.81–3.18); CHA2DS2-VASc6: 5.04% per year (95% CI 4.59–5.60).
doi:10.1371/journal.pone.0169095.g002
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Discussion
In this study, we confirmed that the risk of TE increases with an increasing CHA2DS2-VASc
score in Asian HF patients in sinus rhythm. We also established that chronic ischemic heart
disease and chronic kidney disease are independent predictors of TE among HF patients in
sinus rhythm, incorporation of which into the CHA2DS2-VASc score modestly improves its
predictive value.
Observational studies and post-hoc analyses from HF trials have shown that HF patients in
sinus rhythm are at high risk of TE.[2–5] In our study, although the risk of TE was lower
among HF patients in sinus rhythm than those with AF, the annual incidence was 2.91% per
year, markedly higher than the reported incidence of 1.45 per 1000 persons per year in the gen-
eral population.[31] Nevertheless, the risk of TE is not the same among all HF patients in sinus
rhythm. Prior studies of a Danish registry have shown that the risk of TE increases with an
increasing CHA2DS2-VASc score.[4, 21] We found a similar difference in the annual incidence
of TE among HF patients with different CHA2DS2-VASc score. More importantly, both our
study and the Danish study showed that a CHA2DS2-VASc score of 1 was associated with only
modestly increased risk of TE.[21] Even in those who had a CHA2DS2-VASc score of 2–3, the
annual incidence of TE was still less than 2% per year. In these patients, the benefit of anticoa-
gulation may not outweigh the risk of the therapy. This may partially explain the negative
results from previous randomized controlled trials that tested the benefit of anticoagulation
Fig 3. Receiver-Operating Characteristics curves for the CHA2DS2-VASc and the CHA2DS2-VASc-HK2
score to predict thromboembolic events among heart failure patients in sinus rhythm. The area under
the curve for the CHA2DS2-VASc score was 0.57 (95% CI 0.54–0.59) and that for the CHA2DS2-VASc-HK2
score was 0.61 (95% CI 0.58–0.63). A significant improvement in the area under the curve was noticed after
incorporation of chronic ischemic heart disease and chronic kidney disease into the CHA2DS2-VASc score
(p = 0.022).
doi:10.1371/journal.pone.0169095.g003
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therapy among HF patients in sinus rhythm.[10–13] Future randomized study is needed to
properly assess the value of anticoagulation therapy among the high-risk subgroup of HF
patients.
In this study, chronic ischemic heart disease and chronic kidney disease were independent
predictors of TE. By incorporating these parameters into the CHA2DS2-VASc score, we mod-
estly increased its predictive value from 0.57 (95% CI 0.54–0.59) to 0.61 (95% CI 0.55–0.66;
p = 0.022). Furthermore, the new CHA2DS2-VASc-HK2 score was able to stratify HF patients
in sinus rhythm into low (annual incidence of TE<2% per year), intermediate (annual
Fig 4. Risk of thromboembolic events among heart failure patients in sinus rhythm according to their
CHA2DS2-VASc-HK2 score. (A) Kaplan-Meier curves for thromboembolic event-free survival. Log-rank: 25.896.
P<0.001. (B) Annual incidence of thromboembolic events. CHA2DS2-VASc-HK2 = 1–3: 0.86% per year (95% CI
0.78–0.96); CHA2DS2-VASc-HK2 = 4–7: 2.76% per year (95% CI 2.61–2.92); CHA2DS2-VASc-HK28: 5.50% per
year (95% CI 4.99–6.12).
doi:10.1371/journal.pone.0169095.g004
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incidence of TE 2–5% per year) or high (annual incidence of TE>5% per year) thromboem-
bolic risk. Nevertheless, the relatively low area under the ROC curve implies that there remain
significant missing variables in the new scoring system. In a pooled analysis of two clinical tri-
als largely consisting of patients with chronic HFREF, Abdul-Rahim and colleagues have
shown that age, previous stroke, New York Heart Association class, diabetes mellitus treated
with insulin and body mass index predicted stroke in HF patients without AF.[5] We did not
include New York Heart Association class or body mass index in our analysis, as both parame-
ters are dynamic and particularly inaccurate in patients with new-onset HF.[5] Furthermore,
we did not find prescription of insulin predictive of TE, in contrast to the findings by Abdul-
Rhaim et al.[5] This is not surprising, as prescription of insulin in real-life situation can be
affected by many factors. Other than secondary oral drug failure and chronic renal failure,
availability of new oral hypoglycemic agents, perceived risk of tight diabetic control, accept-
ability and practicability of insulin injection, all affect one’s decision on prescribing insulin to
a patient.
More recently, Abdul-Rahim et al. have published another study comprising patients from
two clinical trials of chronic HFPEF.[32] They have found that patients with HFREF and
HFPEF share similar risk factors for stroke.[32] In addition, they have shown that the risk
model derived from the HFREF cohort predicts stroke in patients with HFPEF with compara-
ble c-index.[5, 32] Similarly, our study did not find any significant differences in the ability of
the CHA2DS2-VASc-HK2 score in predicting TE among patients with HFREF and HFPEF.
These findings suggest that although the risk factors for HFREF and HFPEF are different, the
risk factors for TE in HF remain similar. Furthermore, post-hoc analyses of previous clinical
trials have not consistently shown that LVEF is a risk factor for TE in patients with HF.[33–35]
In addition, the study by Abdul-Rahim et al. has not shown that LVEF predicts TE in HF
patients.[5] It is likely that other factors leading to the common pathophysiologic pathway of
inflammation, hypercoagulability, endocardial and endothelial dysfunction play a more
important role in TE among HF patients than intracardiac stasis associated with LV systolic
dysfunction per se.[2, 7–9]
Although both the CHA2DS2-VASc score and the CHA2DS2-VASc-HK2 score demon-
strated limited predictive ability of TE as shown in the ROC analyses, both scoring systems
Table 3. Prediction of thromboembolic events in 1,202 heart failure patients in sinus rhythm using the
CHA2DS2-VASc score and the CHA2DS2-VASc-HK2 score.
HR (95% CI) p-value
CHA2DS2-VASc score1 1.27 (1.13–1.44) <0.001*
CHA2DS2-VASc score2 0.001*
1 Reference
2–3 2.9 (0.39–22.1) 0.300
4–5 5.4 (0.74–38.84) 0.095
6 9.0 (1.23–65.28) 0.030*
CHA2DS2-VASc-HK2 score1 1.28 (1.17–1.40) <0.001*
CHA2DS2-VASc-HK2 score2 <0.001*
1–3 Reference
4–7 3.14 (1.36–7.24) 0.007*
8 6.12 (2.58–14.49) <0.001*
*p<0.05.
1. Continuous variable.
2. Categorical variable.
doi:10.1371/journal.pone.0169095.t003
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involve simple calculation by summing up objective clinical risk factors, which improves their
applicability as a risk stratification tool. External validation of the CHA2DS2-VASc-HK2 score
is required to assess the robustness of this scoring system in predicting TE among HF patients
in sinus rhythm.
A major strength of this study is that complete records for all patients were available, such
that all baseline and outcome variables were adjudicated. In addition, patients in our study
were followed up for a considerably long period of time. However, our study also has limita-
tions. First, not all patients in our study had an echocardiogram performed on admission. As a
result, our study might be underpowered to evaluate the effect of LVEF on TE. Nevertheless,
our finding that LVEF was not predictive of TE is echoed by the result of another study com-
prising patients of clinical trials.[5] Second, although the incidence of TE was much higher in
the HF than the general population, the actual number of events in each of the HFREF and
HFPEF group was small due to small sample size, which precluded detailed subgroup analyses.
However, previous study by Abdul-Rahim et al. has shown that the risk factors for stroke in
HFREF and HFPEF are similar. Furthermore, we did not find any significant differences in
the ability of the CHA2DS2-VASc-HK2 score in predicting TE among patients with HFREF
and HFPEF. Third, patients were not systemically followed up for the development of AF. It is
possible that some patients had undiagnosed paroxysmal AF prior to the development of TE.
Forth, it is usually not possible to delineate the actual mechanism of ischemic cerebrovascular
events.[36] As a result, the exact proportion of cardioembolic stroke versus ruptured athero-
sclerotic plaque remains undetermined.
Conclusions
HF, even without AF, is associated with a high incidence of TE. The CHA2DS2-VASc score is
useful in stratifying thromboembolic risk among this group of patients. Incorporation of
chronic ischemic heart disease and chronic kidney disease into the scoring system confers a
modest but significant improvement in the ability to predict TE among HF patients in sinus
rhythm.
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